Bortezomib Equity 3.5 mg Powder for Solution for injection
PDF Leaflet Revision Date: 25 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 twice weekly for 2 weeks, followed by a 10-day rest.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; potential fetal hazards. Discontinue breastfeeding during treatment.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral hypoglycemics
Contraindications
- Hypersensitivity to bortezomib
- Acute diffuse infiltrative pulmonary disease
Common side effects
- Nausea
- Diarrhoea
- Constipation
- Fatigue
- Thrombocytopenia
Counselling Points
- Use effective contraception during treatment
- Monitor for signs of infection
- Report any neurological symptoms immediately
Serious warnings
- Do not administer intrathecally
- Risk of severe neuropathy
- Potential for PML
Important Disclaimer
The Bortezomib Equity 3.5 mg Powder for Solution for injection professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
